Buy or sell AiCure stock pre IPO via an EquityZen fund
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress.
About AiCure Stock
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress. IMA provides visual dose confirmation, interactive patient support and engagement, and visual diagnostic capabilities. The platform has been validated to improve patient behavior in randomized controlled trials. In clinical research, AiCure is increasing the probability of trial success and introducing more objective clinical endpoints. In population health, AiCure is enabling intelligent decision-making and improving health outcomes. By 2020, there will be a one million nurse shortage in the US. AiCure is striving to help fill this gap. In clinical research, approximately one quarter of clinical trials fail due to a lack of patient oversight, contributing to over $40 billion in annual losses. AiCure is seeking to accelerate better medications into the market.
Chief Product Officer
Co-Founder & CSO
Co-Founder & CEO
AiCure Raises $12.25 Million For Its Treatment Monitoring Technology
TechCrunch - Jan, 13 2016